FDA De Novo Classification Strategy

Establishing a New Regulatory Category

One of the most significant achievements of the engagement was positioning the client’s technology to establish a new FDA device classification.

Successful De Novo authorization would allow future manufacturers developing substantially equivalent technologies to pursue the 510(k) pathway using the newly classified device as a predicate.

This outcome not only benefited the client but also contributed to the broader evolution of medical technology regulation.

Outcome

By the conclusion of the engagement, the company possessed a comprehensive regulatory strategy supported by a mature quality management system, well-defined software lifecycle documentation, robust clinical evidence planning, integrated risk management, and a scientifically defensible De Novo submission.

Perhaps most importantly, executive leadership gained confidence that commercialization decisions were being driven by sound regulatory science rather than assumptions or incomplete information.

The engagement transformed regulatory affairs from a perceived compliance function into a strategic business capability supporting innovation, investment, and long-term growth.

Business Impact

The benefits extended well beyond regulatory planning.

Engineering teams gained clearer development priorities. Clinical investigators conducted studies aligned with FDA expectations. Investors viewed the strengthened regulatory strategy as evidence of organizational maturity. Product managers were able to develop commercialization plans with greater confidence, while quality personnel implemented processes capable of supporting future software releases and product expansions.

Most significantly, the company established itself as a pioneer within its emerging technology category, creating opportunities for future product development and market leadership.